A proposed Parkinson’s therapy targets extracellular alpha-synuclein
Original source
Polymeric lysosome-targeting chimeras for extracellular α-synuclein degradation in Parkinson's disease. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
Related topics
A journal article proposes polymeric lysosome-targeting chimeras, called PolyTACs, to capture and degrade extracellular alpha-synuclein. The approach is intended for Parkinson’s disease and has not been shown in the supplied source to work in amyotrophic lateral sclerosis (ALS) or motor neurone disease (MND).
Why this matters
This does not currently change treatment for people with ALS or MND. The article only suggests that the platform might eventually be adaptable to proteins such as TDP-43, pending further validation.
Limitations and context
The supplied source is a proposal and review, not evidence of clinical benefit. It does not report results in people, animals or ALS/MND. Any application to TDP-43 or other proteinopathies remains unvalidated.